TScan Therapeutics

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

Amgen

Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass.

AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

Company to host a virtual event to discuss highlights from its Phase 1 umbrella trial of TSC-100 and TSC-101 on Wednesday, May 17, 2023, at 5:30 p.m. ET Company to host a virtual event to discuss highlights from its Phase 1 umbrella trial of TSC-100 and TSC-101 on Wednesday, May 17, 2023, at 5:30 p.m. ET

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

Deepens the Board's clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance

TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as acting CEO

TScan Therapeutics Announces CEO Transition

Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Barclays Global Healthcare Conference being held at the Loews Miami Beach Hotel in Miami Beach, FL on Wednesday, March 15, 2023 at 4:05 p.m. Eastern Time.

TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker data by mid-year 2023

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 8, 2023, at 2:10 p.m. Eastern Time.

TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 3:30 p.m. Eastern Time.

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

BiondVax Pharmaceuticals

Tritium DCFC Ltd

Intelligent Bio Solutions Inc

Ryvyl Inc

Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch After Big News This Week

Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation

TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022

WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 15th annual employee-based survey project from The Boston Globe. The Top Places to Work 2022 was published online at Globe.com/TopPlaces and will appear in the Globe Magazine on Sunday, December 4, 2022. TScan ranks as the top midsize biotechnology company, and 8th out of the top fifty midsize companies overall in the Top Places to Work in Massachusetts in the 15th annual employee-based survey project.

TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022 at 10:55 a.m. ET.

TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference

TCRs for an HLA-A*02:01 epitope of PRAME now in IND-enabling studies

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting

Four sites for hematologic malignancies program open and enrolling patients

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors

TScan Therapeutics Announces Upcoming Virtual Investor Event

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of a trial in progress abstract related to its lead candidates, TSC-100 and TSC-101, at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 10-13, 2022, in New Orleans.

TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.

TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

Financing supports management's focus on clinical execution and advancing its ImmunoBank

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held at the Sheraton New York in New York, NY on Wednesday, September 14, 2022 at 12:55 p.m. ET.

TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Phase 1 umbrella trial for hematologic malignancies open for enrollment

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David P. Southwell, President and Chief Executive Officer, will participate in a virtual panel discussion titled “A View to a Kill(er Cell)” at the 13th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022 at 1:10 p.m. ET.

News for TScan Therapeutics Stock (TCRX)